The Prognostic Value of 2-Deoxy-2-[18F]Fluoro- d -Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

Purpose To explore the prognostic value of 2-deoxy-2-[18F]fluoro- d -glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Results Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. Conclusion FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.